ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
September 05, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
August 29, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation.Top-line trial data are expected to be issued in a...
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
June 15, 2017 07:04 ET
|
ProQR Therapeutics N.V.
Key program features and updates: ProQR to host an R&D day in New York today, June 15, from 8:00am to 1:00pm Eastern Standard Time. The live webcast can be accessed at...
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
June 08, 2017 09:03 ET
|
ProQR Therapeutics N.V.
Key Updates An oral presentation on the final results from the proof-of-concept (PoC) nasal potential difference (NPD) trial will be given by Steve Rowe, MD at the European Cystic Fibrosis Society...
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
May 31, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients...
ProQR Announces Results for the First Quarter of 2017
May 17, 2017 07:00 ET
|
ProQR Therapeutics
Key updates QR-010 Phase 1b clinical trial on track to present top-line data in cystic fibrosis (CF) patients in mid-2017.Investigational new drug (IND) application for QR-110, ProQR’s lead program...
ProQR remembers co-founder Henri Termeer after his unexpected passing
May 15, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away...
ProQR Announces R&D Day in New York on June 15
May 09, 2017 07:00 ET
|
ProQR Therapeutics
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ETPresentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis...
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET
|
ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...